Iimveliso

1.Ukuphanda ukuba ngaba i-adenosine diphosphate (ADP)-derived adenosine inokuthintela ukuhlanganiswa kweplatelet, ngakumbi phambi komphikisi we-P2Y₁₂, apho iziphumo ze-ADP kwi-receptor ye-P2Y₁₂ ziya kuthintelwa. i-peptide ngokubalwa kweplatelet kwi-platelet-rich plasma (PRP) kunye negazi elipheleleyo phambi kwe-ADP kunye ne-P2Y₁₂ abachasi be-cangrelor, i-prasugrel esebenzayo ye-metabolite, kunye ne-ticagrelor.Ebukhoneni bomchasi we-P2Y₁₂, i-preincubation ye-PRP kunye ne-ADP inhibited aggregation;esi siphumo sapheliswa yi-adenosine deaminase.Akukho kuvinjelwa kokuhlanganiswa okwenzeka kwigazi elipheleleyo ngaphandle kokuba i-dipyridamole yongezwa ukuze inhibithe i-adenosine kwi-erythrocytes.Imiphumo ye-ADP kwi-PRP kunye negazi elipheleleyo liphindwe kusetyenziswa i-adenosine kwaye ihambelana ngokuthe ngqo neenguqu kwi-cAMP (ihlolwe yi-vasodilator-stimulated phosphoprotein phosphorylation).Zonke iziphumo zazifanayo kungakhathaliseki ukuba i-agonist ye-P2Y₁₂ isetyenzisiweyo.I-ADP inqanda ukuhlanganiswa kweplatelet phambi komphikisi we-P2Y₁₂ ngokuguqulwa kwi-adenosine.Ukuvinjelwa kwenzeka kwi-PRP kodwa kungekhona kwigazi elipheleleyo ngaphandle kokuba i-adenosine uptake inhibited.Akukho namnye wabachasi be-P2Y₁₂ abaphonononge iziphumo ze-dipyridamole kwiimvavanyo ezenziweyo.

I-2.ADP ithathwa njenge-agonist ebuthathaka yeplatelet ngenxa yeempendulo ezilinganiselweyo zokudibanisa eyenza i-vitro kwi-physiological concentrations of extracellular Ca (2+) [(Ca (2+) )) (o) ].Ukwehliswa [Ca(2+) ](o) ngokuxakayo kwandisa i-ADP-evoked aggregation, isiphumo esibalelwa ekuphuculweni kwemveliso yethromboxane A(2).Olu pho nonongo luhlolisise indima ye-ectonucleotidases kwi- [Ca (2+)] (o) -ukuxhomekeka kokusebenza kweplatelet.Ukunciphisa [Ca(2+) ](o) ukusuka kumanqanaba e-millimolar ukuya kwi-micromolar eguqulelwe kwi-ADP (10 μmol/l)-ikhuphe udibaniso lweplatelet ukusuka kwi-transient ukuya kwimpendulo ezinzileyo kuzo zombini iiplasma eneplatelet-rich kunye nokumiswa kokumiswa.Ukuthintela i-thromboxane A (2) imveliso kunye ne-aspirin ayizange ibe nefuthe kule [Ca (2+) ] (o) -ukuxhomekeka.Ukuthintelwa kokuthotywa kwe-ADP kuphelise iyantlukwano phakathi kwe-low kunye ne-physiological [Ca(2+) ](o) ekhokelela kuhlanganiso olomeleleyo noluzinzileyo kuzo zombini iimeko.Imilinganiselo ye-ADP ye-extracellular ibonakalise ukuthotywa kokunciphisa kwi-plasma kunye ne-apyrase-equlethe i-saline ye-micromolar xa kuthelekiswa ne-millimolar [Ca (2+)] (o) .Njengoko bekuxeliwe ngaphambili, isizukulwana se-thromboxane A (2) saphuculwa ngaphantsi [Ca (2+) ] (o) , nangona kunjalo oku bekuzimeleyo kumsebenzi we-ectonucleotidase (.) I-P2Y i-receptor antagonists cangrelor kunye ne-MRS2179 ibonise imfuneko ye-P2Y (12) i-receptors kwi-ADP-evoked aggregation ezinzileyo, enendima encinci ye-P2Y(1) .Ukuqukumbela, i-Ca (2+) -umsebenzi oxhomekeke kwi-ectonucleotidase yinto ephambili emisela ubungakanani beplatelet aggregation kwi-ADP kwaye kufuneka ilawulwe kwizifundo ze-P2Y receptor activation.